verapamil (1 Oug ml-1) increased by 1.5 times the [14C]-melphalan accumulation by murine bone marrow, reversibly and independently of external calcium. Efflux of [14C]-melphalan from murine bone marrow was retarded by verapamil. Verapamil increased [I4C]-melphalan uptake by disaggregated fibrosarcoma cells but had no effect on melphalan accumulation and cytotoxicity in human bone marrow. Although verapamil affected melphalan pharmacokinetics, enhancement of cellular melphalan uptake by verapamil in murine fibrosarcoma and bone marrow appeared to account for much of the increase in melphalan cytotoxicity. The lack of potentiation of melphalan by verapamil in human marrow suggests differences in melphalan transport or in verapamil membrane interactions in mouse and man.
Treatment of tumours is limited by their resistance to chemotherapeutic drugs, either inherent or acquired during treatment. Melphalan is widely used in the treatment of multiple myeloma, ovarian and breast cancer, and has recently been used in high intravenous doses in multiple myeloma, acute leukaemia, solid tumours and paediatric tumours (Hedley et al., 1978; Pritchard et al., 1982; Maraninchi et al., 1983; McElwain & Powles, 1983) . The dose limiting toxic effects of melphalan are on the bone marrow, which can be circumvented by autologous marrow transplantation (McElwain et al., 1979) , and on the gastrointestinal tract (Millar et al., 1978b, c) . Priming somewhat ameliorates the toxicity of melphalan (Hedley et al., 1978; Millar et al., 1978a) , but new approaches are needed to improve the therapeutic index and to circumvent resistance.
Verapamil is a calcium channel blocker which reduces excitation-contraction coupling in cardiac and smooth muscle cells (Fleckenstein, 1977) . Verapamil increases cellular accumulation of vinca alkaloids and anthracyclines and increases cytotoxicity in vitro and in vivo in resistant sublines, and some parent lines, of murine P388 leukaemia, Lewis lung carcinoma, Ehrlich ascites, human B16 melanoma, colon adenocarcinoma, bladder and ovarian carcinoma (Tsuruo et al., 1981; Rogan et al., 1984; Slater et al., 1982; Simpson et al., 1984; Yanovich & Preston, 1984 (Ramu et al., 1984) ; verapamil is thought to interact with the cell membrane and decrease active extrusion (Tsuruo et al., 1981 ; Kessel & Wilberding, 1984; Murray et al., 1984; Skovsgaard et al., 1984) .
Melphalan is taken into cells by two separate amino acid transport systems Vistica, 1983) , and efflux occurs through different undefined pathways. Rogan et al. (1984) reported that verapamil had no effect on the cytotoxicity of melphalan in a melphalan-resistant human ovarian carcinoma cell line. The recent findings of verapamil potentiation of etoposideinduced DNA damage and cytotoxicity in L1210 cells in vitro, with decreased etoposide efflux (Yalowich & Ross, 1984; 1985) , and the cross resistance to melphalan of chinese hamster ovary cells exhibiting pleiotropic drug resistance (Ling et al., 1983) Withers and Elkind (1970) (Millar et al., 1978b) . The number of regenerating crypts per circumference was expressed as a fraction of the number of crypts per circumference in untreated normal mice, and compared as the mean + s.e.r. using the t test for small samples.
Spleen colony assay
The spleen colony forming cells of mouse bone marrow (CFU-S) were assayed by the method of Till and McCulloch (1961) . Mice were treated with i.p. melphalan and/or verapamil and were killed with control animals one day later for CFU-S assay. Results of 3 experiments were similar and were combined.
Clonogenic assay, CFU-GM The mononuclear fraction of human and mouse bone marrow was obtained by centrifugation at 400g for 30min over a Ficoll/sodium metrizoate solution (Lymphoprep, specific gravity 1.077, Nyegaard). Cells were incubated in the presence of melphalan (0.01-2 pg ml -1) and/or verapamil 10pgml-1 at 37°C for 60min, washed and resuspended in drug-free medium. Then the colony forming ability of the mononuclear cell fraction (CFU-GM) was assayed following the method of Bradley and Metcalf (1966) plating each treatment group in triplicate. Colony stimulating factor was derived from pregnant mouse uterus (PMUE) for mouse marrow, and from 5637 human bladder carcinoma cells for human marrow (Myers et al., 1984) .
In vitro ['4C]-melphalan uptake and efflux
The mononuclear cell fraction of bone marrow and disaggregated fibrosarcoma cells, separated from red cells by centrifugation over Lymphoprep, were adjusted to 2-3 x 106 cells ml-' in PBS. No amino acids were present in the medium Vistica, 1983) . Verapamil (0.1 to 100gm1-1) was added, and finally [14C]-melphalan, 1 ig ml 1, and the cells incubated at 37°C for 60 min. Then using a method adapted from Martin et al. (1982) , duplicate 1ml aliquots were layered over 0.5ml oil (mineral oil:silicone oil (Dow Corning), 1:4) and spun at 12,000g for 2-3min in a microcentrifuge 320a (Burkard Scientific Sales Ltd). The cell pellets were solubilised in Protosol (New England Nuclear) and added to 10ml of ACS scintillant (New England Nuclear) containing acetic acid 37.5 ml gallon-1. Samples and aliquots of supernatant were counted in a liquid scintillation counter (Intertechnique Martin et al., 1982) , because plateau levels of [14C]-melphalan were compared. The results from 2 or more experiments were combined, as mean ±s.e.r. For [14C]-melphalan efflux studies, cells were loaded by 30 min incubation in 1 ,ug ml-' [14C]_ melphalan. Duplicate 1 ml samples were taken (and spun through oil) and the remaining cells spun down and resuspended in ice cold medium to prevent immediate efflux (Goldenberg et al., 1977; Begleiter et al., 1982; Martin et al., 1982) . The cells were then incubated at 37°C without melphalan, in the presence or absence of verapamil, with samples being taken immediately and up to 30 min later.
In one experiment, murine bone marrow cells increased absorption of i.p. melphalan. This pharmacokinetic effect was still present with verapamil 5mg kg-1 i.p. but was negligible for verapamil 2.5 mg kg-1 i.p. (Figure 2 ).
Normal tissue toxicity of melphalan in mice: Effect of verapamil The jejunum microcolony assay, performed twice, showed potentiation of the toxicity of melphalan by 10mg kg-' verapamil i.p. for melphalan doses of 15-20mgkg-' i.p. (Figure 3 ). In the CFU-S assay melphalan cytotoxicity to murine bone marrow stem cells was increased significantly by treatment with verapamil 10mgkg-1 i.p. but not by the lower doses of 5 and 2.5mgkg-' i.p. (Figure 4 ). Verapamil 10mg kg-1 i.p. alone had no effect in either assay. Thus verapamil increased melphalan toxicity to the two most sensitive normal tissues, gastrointestinal tract and bone marrow. (3 pigml-1) for 4 tumour cell lines (Tsuruo et al., 1981; . In contrast, verapamil (lOgml-1) had no effect on melphalan cytotoxicity to the mononuclear cell fraction of human bone marrow ( Figure Sb) lymphoblasts and LPC-1 plasmacytoma cells (Goldenberg et al., 1977; Martin et al., 1982; Vistica, 1983 experiments.
fibrosarcoma cells 70-85%, and remained constant within each experiment during the 60 min incubation. Verapamil's calcium channel blocking action is overcome by increasing extracellular calcium concentration (Fleckenstein, 1977) . However, addition of calcium to the medium had no effect on
[14C]-melphalan uptake, nor on its enhancement by verapamil 10 ug ml -, in murine bone marrow (Table II) . Because high concentrations of calcium precipitated phosphate when added to PBS, the second experiment (b) was performed in BSS. Although addition of melphalan (in acid alcohol) to BSS lowered pH cell viability was maintained for the 60 min. (Tsuruo et al., 1981; Skovsgaard et al., 1984) (Goldenberg et al., 1977; Begleiter et al., 1979) and it is likely that most of the [14C]-melphalan enters the cells unhydrolysed, and then becomes hydrolysed or bound. Verapamil had no effect on melphalan hydrolysis in the medium, but appeared to increase uptake of unhydrolysed melphalan. 
Discussion
Treatment with verapamil of CBA mice bearing two fibrosarcomas potentiated the antitumour effect of melphalan assessed by growth delay, this effect being greater in FS12 which was less sensitive to melphalan. The higher blood levels and greater area under the curve for melphalan in the presence of verapamil could have explained both this effect and the potentiation of bone marrow stem cell and gastrointestinal toxicity, if it were not for the twofold enhancement by verapamil of melphalan cytotoxicity to murine bone marrow in the in vitro CFU-GM assay. Verapamil increased murine bone (Goldenberg et al., 1977 Martin et al., 1982) , and also in murine bone marrow in our experiments. Active uptake occurs through two amino acid transport systems, the L system and the more readily saturable, sodium-dependent ASC-like system, both of which are inhibited by physiological concentrations of Lleucine and L-glutamine Goldenberg et al., 1979; Vistica, 1983) . Efflux of melphalan is temperature-dependent but occurs through different, poorly defined pathways (Goldenberg et al., 1977; Begleiter et al., 1982) . Both amino acid uptake systems have been identified in human MCF-7 breast carcinoma cells and peripheral blood lymphocytes , but in murine bone marrow progenitor cells, detected in CFU-GM assay, the sodiumindependent L system is either lacking or has altered affinity for bicyclic amino acids (Vistica, 1980; Vistica et al., 1983) .
In this report, uptake of melphalan was determined in the mononuclear cell fraction, including stem cells, progenitor cells (making up at least 1/200 cells), differentiating and mature cells. However, the similar enhancement of both melphalan cytotoxicity to progenitor cells and melphalan accumulation by mononuclear murine bone marrow cells suggests that verapamil enhanced melphalan uptake not only in the CFU-GM fraction but also in the majority of the other marrow cells. Verapamil's effect in murine but not human bone marrow might be related to the much reduced or absent activity of the L system in murine bone marrow (Vistica, 1980) , for our experiments do not exclude an additional effect on influx. However, differences in the cell membrane, and verapamil's interaction with it, are a more likely explanation. Verapamil had no effect on melphalan hydrolysis in the medium. Both native and hydrolysed melphalan were increased in murine bone marrow after verapamil, with a greater proportion unhydrolysed compared with the medium, suggesting that verapamil affects transport of unhydrolysed drug. The effect on melphalan transport may be a property of all calcium channel blocking drugs, for preliminary experiments in our laboratory have shown flunarizine (gift of Janssen Pharmaceutical) 1 ug mI-'l-, to enhance [14C]-melphalan uptake by murine bone marrow 1.4 fold.
The effect of verapamil and anticalmodulin agents to decrease anthracycline and vincristine efflux is thought to be mediated either through intracellular calcium and calcium-dependent enzyme activities or through interactions with membrane transport systems (Tsuruo et al., 1981; Beck, 1984; Kessel & Wilberding, 1984; Skovsgaard et al., 1984) . Here, increasing extracellular calcium did not prevent verapamil enhancement of melphalan accumulation in murine bone marrow, consistent with an effect of verapamil on the membrane independent of calcium channel blockade. Melphalan accumulation was reduced in L1210 cells by vincristine and adriamycin (Martin et al., 1982) . Chinese hamster ovary cells with pleiotropic drug resistance associated with expression of membrane P-glycoprotein, induced by anthracyclines or vinca alkaloids, were resistant to melphalan (Ling et al., 1983) . Furthermore, verapamil reverses pleiotropic drug resistance (Curt et al., 1984) . These findings suggest that in some cells melphalan transport, possibly efflux, is linked to transport of anthracyclines, vinca alkaloids and other drugs, and is susceptible to changes in the membrane.
Some cells resistant to melphalan demonstrate reduced melphalan accumulation (Redwood & Colvin, 1980; Vistica, 1983) , and it is hoped that verapamil might enhance melphalan uptake in some melphalan-resistant tumours in man. The failure of verapamil to increase melphalan uptake in human bone marrow would serve to enhance the therapeutic index of melphalan, but verapamil's effect on melphalan pharmacokinetics and gastrointestinal toxicity in man are unknown. If verapamil did enhance the gastrointestinal toxicity of melphalan, the administration of melphalan with verapamil or other anticalmodulin drugs should be cautioned.
